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Background. Focusing on novel drug combinations that target different pathways especially apoptosis and MAPK could be a
rationale for combination therapy in successful treatment of lung cancer. Concurrent use of cyclooxygenase (COX) inhibitors with
arsenic trioxide (ATO)might be a possible treatment option.Methods. Cytotoxicity of ATO, dexamethasone (Dex), celecoxib (Cel),
and Indomethacin (Indo) individually or in combination was determined at 24, 48, and 72 hrs in A549 lung cancer cells.TheCOX-2
gene and protein expression, MAPK pathway proteins, and caspase-3 activity were studied for the most cytotoxic combinations.
Results. The IC
50
s of ATO and Indo were 68.7 𝜇mol/L and 396.5 𝜇mol/L, respectively. Treatment of cells with combinations of
clinically relevant concentrations of ATO and Indo resulted in greater growth inhibition and apoptosis induction than did either
agent alone. Caspase-3 activity was considerably high in the presence of ATO and Indo but showed no difference in single or
combination use. Phosphorylation of p38 and ERK1/2 was remarkable in the concurrent presence of both drugs. Conclusions.
Combination therapy with ATO and Indo exerted a very potent in vitro cytotoxic effect against A549 lung cancer cells. Activation
of ERK and p38 pathways might be the mechanism of higher cytotoxic effect of ATO-Indo combination.
1. Introduction
Health care practitioners face a huge burden caused by lung
cancer. Lung cancer is also responsible for a considerable
share of cancer-induced mortalities, which is estimated to
exceed 800,000 annual deaths worldwide [1]. One clinical
obstacle to successful cure of lung cancer is the resistance
to chemotherapeutic agents. Besides, the side effects of
drug regimens routinely employed in cancer treatment are
associated with the treatment failure. One way to overcome
these complications is to utilize multiple drugs enlisting
various mechanisms to attack the disease [2]. Combination
chemotherapy aimed at increasing cytotoxic efficacy has
experienced a huge evolution over recent decades [2]. A
shared mechanism of resistance towards a chemotherapeutic
drug is the failure of the tumor cells to go into apoptosis.
Hence, interest has been raised to exploit this path to
circumvent drug resistance.
This might justify the routine use of combination
chemotherapy in the treatment programs of lung cancers.
However, treatment efficacy has not always been promising
even when recently formulated combinations were used.This
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has opened a window to explore the utilization of other
agents which might not even be a part of current general
cancer therapy strategies. Arsenic trioxide (ATO) is presently
only used for the treatment of acute promyelocytic leukemia
(APL) under the approval of FDA [3]. Application of ATO in
combination with other agents in different cancers including
lung could potentially provide an effective therapeutic tool.
In addition, there are alternative mechanisms which can
promote the apoptotic death of cancerous cells. A large body
of evidence has shown a significant increase in expression
of cyclooxygenase-2 (COX-2) in variety of cancers [4–6].
Thus, many COX inhibitors have been shown to prevent or
delay development of certain tumors including lung cancer.
It has been reported that nonsteroidal anti-inflammatory
drugs (NSAIDs) including celecoxib and indomethacin can
induce apoptosis in various types of lung cancer cells [7–
10]. Furthermore, dexamethasone, a potent synthetic glu-
cocorticoid which inhibits cyclooxygenase none selectively
[11, 12], is being used in various cancer treatment protocols
to prevent cancer progression and/or avoid side effects of
chemotherapeutic agents [13–15]. However, lines of evidence
of NSAIDs’ antilung cancer effects due to the COX-2 inhibi-
tion are conflicting [9, 10, 16, 17].
It is notable that ATO can induce apoptosis in a variety of
hematologic and solid tumor cancer cells, for which several
mechanisms have been accounted [18–20]. Recently we have
shown that ATO induces apoptosis and caspase-3 activation
in the bone marrow promyelocytes of newly diagnosed APL
patients through upregulation of p38 MAPK and Bax [21].
Despite the good therapeutic effects in APL even at low
concentrations, the results obtained in non-APLpatients have
not been encouraging. For this reason enormous efforts have
been made to provide effective combinations of ATO with
other agents [22–24].
Therefore, this study aimed at investigating the effects of
upstream, selective and nonselective COX inhibition, that is,
dexamethasone, celecoxib, and indomethacin, respectively,
on ATO-induced cell apoptosis in human lung cancer cell
line.
2. Materials and Methods
2.1. Reagents. Arsenic trioxide (As
2
O
3
; ATO) was obtained
from Sina-Darou (Iran) in the stock concentration of 5mM
and then diluted with PBS to a working concentration
of 50𝜇M. Dithiothreitol (DTT), Tripure, Western blot
detection kit, XTT assay kit, and polyvinylidene difluo-
ride (PVDF) membrane were from Roche Applied Science
(Germany). Anti-extracellular receptor kinase 1/2 (ERK1/2),
phospho-ERK1/2, p38, phospho-p38, jun N-terminal kinase
(JNK), Akt, Bax, COX-2, and 𝛽-actin antibodies were pur-
chased fromCell Signaling Technology (USA). Bromophenol
Blue, Coomassie blue R-250, and caspase-3 colorimetric
assay kit were purchased from Sigma Chemical Company
(UK). RPMI-1640, Fetal Bovine Serum (FBS), penicillin-
streptomycin, and trypsin-EDTA were purchased from Bio-
Sera (Korea). BioMax film was obtained from Kodak (UK).
M-MuLV, primers, dNTPs, and Taq DNA polymerase were
from Fermentas Life Science (Lithuania). Indomethacin
(Indo) and Celecoxib (Cel) were kindly provided by a collab-
orative lab (as 98.8% purity) [25] and dissolved in minimal
amounts of dimethyl sulfoxide (DMSO) so that the final
DMSO in test wells did not exceed 1%. All other chemicals
were fromMerck (Germany).
2.2. Cell Culture. The A549 cell line (human lung adeno-
carcinoma epithelial cells) was cultured at 1 × 105−1 × 106
cells per mL in RPMI 1640 medium supplemented with 10%
FBS, 100U/mL penicillin, and 100mg/mL streptomycin in a
humidified atmosphere with 5%CO
2
. All the treatments were
carried out on cells in logarithmic phase of growth.
2.3. XTT Assay for Cellular Proliferation. Cells (7,000 cells
per well) were seeded into 96-well flat-bottomed microplates
and let adhere onto the surface. ATO (2–150 𝜇M), Indo (2–
800 𝜇M), Cel (5–150 𝜇M), and Dex (10–200 𝜇M) and their
combinations (at concentrations indicated in the graphs)
were added to thewells. Tomeasure viability, 50𝜇L freshXTT
labeling mixture (49 𝜇L XTT labeling reagent and 1 𝜇L elec-
tron coupling reagent) was added after 24, 48, and 72 hrs and
incubated for 4 hrs at 37∘C in 5%CO
2
atmosphere. Cell viabil-
ity was assayed in quadruplicate, and the whole experiments
were repeated three times. Absorbance at 450 nm (A
450 nm)
of the formazan was measured using a microplate reader,
and the results were expressed as a ratio of the treated cells
over the untreated vehicle cells. Solvent control trials were
performed appropriately and exhibited no cytotoxic effects.
2.4. Protein Isolation andWestern Blotting. Cell extracts were
prepared by lysing the ice-cold PBS washed cells in the
designated times by using 100𝜇L lysis buffer (50mMHEPES,
pH 7.4, 5mMCHAPS, 5mMDTT) at 4∘C for 15min. Extracts
were then centrifuged at 14,000 g in a microfuge at 4∘C,
and supernatants were transferred to fresh tubes. Protein
concentration was determined by Bradford assay method.
Thirty 𝜇g of proteins was added to an equal volume of 2X
SDS-sample buffer and run on a 10% sodium dodecyl sulfate-
polyacrylamide gel (SDS-PAGE). Proteins were transferred
to PVDF membranes (Roche), stained with 0.1% Ponceau S
to ensure equal protein loading, and blocked with 1% casein
in TBS (50mM Tris, 150mM NaCl) for 1 hour at room tem-
perature. The membranes were then hybridized overnight at
4∘C with polyclonal anti-Bax (1 : 2000), anti-Cox-2, anti-p38
(1 : 1000), anti-ERK1/2 (1 : 1000), anti-JNK (1/1000), anti-Akt
(1/1000), anti-phospho-ERK, anti-phospho-p38, and anti-𝛽-
actin (1 : 1000) antibodies (Cell Signaling, USA). Following 2
washes with TBS-T (TBS containing 0.1% Tween-20) and one
wash with TBS for 12minutes each, blots were incubated with
a goat anti-mouse/rabbit-antibody-HRP conjugate (Roche)
for 1 hr at room temperature. After washing the blots as
previously, bandswere visualized by adding luminal substrate
to the blots and exposure to the BioMax film (Kodak).
2.5. Isolation of Total Cellular RNA, cDNA Synthesis, and
RT-PCR. RNA was isolated from log phase cultures of the
cell lines. Cells were harvested by centrifugation at 110 g
BioMed Research International 3
for 5min and washed with PBS and total cellular RNA
was extracted using TRIPURE reagent (Roche, Germany)
following themanufacturer’s instruction. RNA concentration
and its purity were estimated by measuring the absorbance
at 260 and 280 nm. Isolated RNAs were stored at –80∘C
and subsequently used for semiquantitative RT-PCR. Single
stranded cDNA was synthesized using M-MuLV Reverse
Transcriptase (Fermentas, Lithuania) and random hexamer
primers according to the manufacturer’s protocol.
For RT-PCR 1 𝜇g of cDNA was used as the target in a
total volume of 25𝜇L. Reactions were performed according
to standard protocols using the following primers and con-
ditions: for Cox-2 (GenBank: AJ634912.1) forward 5󸀠-AGC
TGGGAAGCCTTCTCTAAC-3󸀠 and reverse 5󸀠-AGATCA
TCTCTGCCTGAGTATCTT-3󸀠 and for𝛽-actin (as internal
control; GenBank: X00351) forward 5󸀠-GAT GAT GAT ATC
GCC GCG CT-3󸀠 and reverse 5󸀠-CTT CTC GCG GTT GGC
CTT GG-3󸀠 primers were used. PCR condition for COX-2
and 𝛽-actin was 35 cycles of denaturation at 94∘C for 30 sec,
annealing at 55∘C for 30 sec, and extension at 72∘C for 30 sec.
PCR products were electrophoresed on a 1.5% agarose gel
containing 500 𝜇g/L ethidium bromide and visualized with
UV light. The amplified bands for COX-2 and 𝛽-actin were
302 and 351 bp, respectively. All experiments were performed
three times.
2.6. Caspase-3 Activity Assay. Activity of caspase-3 was
assayed according to the manufacture guideline (Sigma).
Briefly, 30 𝜇g of lysate, 90𝜇L of assay buffer (20mM HEPES,
pH 7.4, 0.1% CHAPS, 5mM DTT, 2mM EDTA) and 10 𝜇L
of caspase-3 substrate Ac-DEVD-pNA (2mM) were added
to each well of a flat-bottom 96 well. As positive control,
the caspase-3 pure protein was used. For measuring the
nonspecific hydrolysis of the substrate, an inhibitor-treated
cell lysate control was included. Microplate was incubated at
CO
2
incubator and O.D. 405 nm was measured in 4 hrs (in
this time there was the biggest difference).
2.7. Statistical Analysis. Statistical analysis was done using
SPSS software (version 11.0). Data were expressed as Mean ±
SD. One-way analysis of variance (ANOVA), followed by
the Tukey HSD, was used to assess significant differences
between treatment groups. Differences were considered as
significant when 𝑃 < 0.05. The IC
50
was calculated using
Probit command in the SPSS.
3. Results
3.1. Arsenic Trioxide Inhibits the Growth of A549 Cells
Dose- and Time-Dependently. ATO-induced inhibition of
cell growth in A549 is illustrated in Figure 1. To explain
further, a decrease in viability alongwith dose increments and
time extensions is evident. Since the 24 and 48 hrs treatments
had no significant cytotoxicity, assays were focused on the
72 hrs treatment. The dose-response curve of ATO, Cel,
Indo, and Dex on cell proliferation at 72 hrs is shown in
Figure 2. All the drugs, except Dex, induced cytotoxicity in
a dose-dependent manner at 72 hrs. The calculated IC
50
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Figure 1: Effect of different incubation time on the cytotoxicity of
ATO on the A549 cell line (Mean ± SE, 𝑛 = 4; ∗∗𝑃 < 0.01 and ∗∗∗𝑃 <
0.001; ¶¶¶𝑃 < 0.001 compared to ATO 2 𝜇M).
(concentration causing 50%growth inhibition) of agentswere
68.7, 98.2, and 396.5 𝜇M for ATO, Cel, and Indo, respectively.
Dex did not inhibit cell growth up to 200𝜇M (Figure 2).
3.2. Arsenic Trioxide in Combination with Indo, and Not Dex
or Cel, Produces More Potent Growth Inhibition Than with
Either Agent Alone. Because ATO, Cel, and Indo had fairly
high IC
50
as single agent, we hypothesized that combination
of these drugs would bemore efficient to suppress the growth
of the cells. We also tested the effect of Dex on the cytotoxic
effect of ATO. Thus, cells were treated with combinations
of Indo (1, 10, and 50 𝜇M), Cel (5, 25, 50, and 75 𝜇M), Dex
(1, 5, and 50 𝜇M), and 2, 5, and 10 𝜇M concentrations of
ATO for 72 hr and cytotoxicity was measured. As shown
in Figure 3(a), Indo has no cytotoxic effect at 1, 10, and
50 𝜇M. However, combinations of noneffective doses of ATO
(2, 5 𝜇M) and Indo (1, 10 𝜇M) have significantly decreased
the viability of A549 cells. When cells are treated with the
combination of ATO 2 𝜇M and Indo 10 𝜇M, the viability is
reduced by 30% (Figure 3(d)). Indo 10 𝜇M has significantly
augmented the antiproliferative effect of ATO 5 and 10𝜇M to
60% and 80%, respectively (∗∗∗𝑃 < 0.001 and ∗𝑃 < 0.05,
compared to ATO alone). These results suggest that nonef-
fective dose of Indo (10 𝜇M) has increased the cytotoxicity of
low doses of ATO synergistically. Compared to ATO alone,
combination of Indo 50𝜇M with all the concentrations of
ATO significantly decreased the cell proliferation (∗∗∗𝑃 <
0.001) and Indo 50 𝜇M induced maximum effect on ATO
toxicity. Interestingly a combination of Indo 50 𝜇M and
ATO 5 or 10 𝜇M generates similar growth inhibition to Indo
800 𝜇M alone and 50–100 percent higher than ATO alone.
Figure 3(b) shows the effect of combination of ATO and
Cel on A549 proliferation. Cel has reduced cell proliferation
by 20% at 75 𝜇M (Figure 3(b)); however, this effect is not
significant compared to control. When various doses of Cel
are combined with ATO, the cytotoxicity is similar to ATO
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Figure 2: Effect of different concentrations of ATO (a), Cel (b), Indo (c), and Dex (d) on the growth of A549 cell line (Mean ± SE, 𝑛 = 4).
alone. Although the proliferation is reduced in the combi-
nation of ATO and Cel, the changes are not significantly
different from ATO alone. ATO at low doses (2, 5 𝜇M) has
increased celecoxib 75 𝜇M inhibitory effect and the ATO-
Cel combination exhibits an additive effect (Figures 3(b)–
3(e)). Combination of Dex and ATO treatment did not alter
the antiproliferative effect of ATO in A549 cells (Figures
3(c)–3(f)). Even in low doses of ATO, cotreatment with Dex
slightly increased the proliferation of cells.
3.3. ATO Decreases the Expression of COX-2 mRNA Dose-
Dependently. Considering the role of COX-2 and COX
inhibition in lung cancer [26], we have assessed the mRNA
expression of COX-2 with different concentrations of ATO as
well as ATO 2 𝜇M combination with Indo. Figure 4(a) shows
that ATO has decreased the COX-2 expression in a dose-
dependentmanner (Figures 4(a) and 4(b)) and at ATO 10 𝜇M
there is 50% reduction in COX-2 expression. Treatment of
A549 cells with Indo has increased the COX-2 expression
dose-dependently (Figure 4(c)). The Indo-induced COX-2
expression has been inhibited by addition of ATO 2 𝜇M to
the cells (Figure 4(c)).
3.4. Expression of Cox-2, Akt, ERK1/2, p38, JNK, and Bax
Proteins in the Cells Treated with ATO, Indo, Dex, ATO/Indo,
and ATO/Dex Combinations. To address the role of proteins
involved in the apoptosis and survival, the expression of
Akt, ERK1/2, p38, JNK, and Bax proteins was determined by
western blotting analysis. The expression of COX-2 protein
decreased dose-dependently by ATO especially in the dose of
BioMed Research International 5
0 
20 
40 
60 
80 
100 
120 
140 
1 10 100 1000 
C
el
l g
ro
w
th
 (%
 o
f c
on
tro
l)
+ATO 2 𝜇M
+ATO 5 𝜇M
+ATO 10𝜇M
Indo. 48h
Log indomethacin (𝜇M)
(a)
0 
20 
40 
60 
80 
100 
120 
140 
1 10 100 1000 
C
el
l g
ro
w
th
 (%
 o
f c
on
tro
l)
+ATO 2 𝜇M
Log celecoxib (𝜇M)
+ATO 10𝜇M
+ATO 50𝜇M
Cel. 48h
(b)
0 
20 
40 
60 
80 
100 
120 
1 10 100 1000 
C
ell
 g
ro
w
th
 (%
 o
f c
on
tro
l)
+ATO 2 𝜇M +ATO 50𝜇M
+ATO 10𝜇MDex. 48h.3h
Log Dex (𝜇M)
(c)
120
100
80
60
40
20
0
+ + + + + + + +
+
+ + + + + + +
+
− −
−
−
−
−
−+ −− − −+
+
−
− − −
− − −+ −− − −
+− −− −
+−−−
− −−−
−
+
+−−−
− −−−
−
+
+−−−
− −−−
−
− +− − −−
+
+−−
− −−
−
+− − −
ATO
Indo. (1𝜇M)
Indo. (10𝜇M)
Indo. (50𝜇M)
Indo. (100𝜇M)
ATO 2 𝜇M ATO 5 𝜇M Indo.
C
el
l g
ro
w
th
 (%
 o
f c
on
tro
l)
∗∗∗ ∗∗∗ ∗
ATO 10𝜇M
(d)
+ + + + + + + +
+
+ + + + + + +
+
− −
−
−
−
−
−+ −− − −+
+
−
− − −
− − −+ −− − −
+− −− −
+−−−
− −−−
−
+
+−−−
− −−−
−
+
+−−−
− −−−
−
− +− − −−
+
+−−
− −−
−
+− − −
120
100
80
60
40
20
0
C
el
l g
ro
w
th
 (%
 o
f c
on
tro
l)
∗∗∗
ATO
Cel. (5𝜇M)
Cel. (25𝜇M)
Cel. (50𝜇M)
Cel. (75𝜇M)
Dex.ATO 2 𝜇M ATO 5 𝜇M ATO 10𝜇M
(e)
+ + +
+
+
+
+ + + + + +
+
+ +
+
+
+
− −
−− − −+− − −+− −
−
−
−−
−
− + −−−
− +−−−
+ −−−
+−−−
− −
−−
−
−
140
120
100
80
60
40
20
0
C
el
l g
ro
w
th
 (%
 o
f c
on
tro
l)
∗
ATO
ATO 50𝜇MATO 10𝜇MATO 2𝜇M Dex.
Dex. (10𝜇M)
Dex. (5𝜇M)
Dex. (1𝜇M)
(f)
Figure 3: Inhibitory effects of single (a–c) and combination (d–f) of ATO and Indo, Cel and Dex on A549 lung cancer cell proliferation
(Mean ± SE, 𝑛 = 4; ∗𝑃 < 0.05, ∗∗𝑃 < 0.01 and ∗∗∗𝑃 < 0.001).
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Figure 4: The effects of ATO and Indo and their combinations on the expression of COX-2 mRNA. (a) RT-PCR reaction products were
resolved on 1% agarose gel and stained with Ethidium bromide. (b) Densitometric analyses of COX-2 mRNA expression is presented as the
band’s density to control (𝛽-actin) of three independent experiments (Mean ± SE, 𝑛 = 3). (c) The effect of Indo alone (light columns) and
combination with ATO 2𝜇M (dark columns) on COX-2 expression.
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Figure 5: Western blot analysis of COX-2, Akt, ERK1/2, p38, JNK, and Bax proteins in A549 cells treated with ATO, Indo, Dex, ATO + Indo,
and ATO + Dex combinations.
50𝜇M (Figure 5). Indo alone did not change the expression
of COX-2 protein. However, combination of ATO 2 𝜇M and
Indo (2 and 10 𝜇M) decreased the COX-2 protein expres-
sion. ERK1/2 and p38 proteins levels were decreased with
50𝜇M ATO treatment but remained unchanged with other
treatments. Akt, Bax, and JNK seemed to be unchanged with
different treatments.
Dex alone and in combination with ATO decreased
expression of COX-2 protein completely. Furthermore,
Dex decreased p38 and ERK1/2 proteins expressions dose-
dependently which remained unaltered in combination with
ATO.
3.5. ERK and p38 Proteins Were Highly Phosphorylated in
the Cells Treated with ATO/Indo Combination. Since the
change in the total ERK and p38 protein expressions was
remarkable, we investigated the phosphorylation of ERK and
p38 proteins in the ATO, Indo and ATO/Indo treatments.
As shown in Figure 6, treatment of A549 cells with ATO
and Indo alone lowered the phospho-ERK at 24 hrs; however,
4h 24h
Phospho-ERK
Phospho-p38
−
− −
−
+ +
+ + ++
+ +
Indo. (10𝜇M)
ATO (2𝜇M)Cont.
Figure 6: Phosphorylation of p38 and ERK in A549 cells treated
with ATO, Indo, and ATO/Indo combination.
in cells treated with both ATO/Indo, the phosphorylation
of ERK was increased and reached maximum level at 24 hr.
Phosphorylation of p38 did not change in ATO and Indo sin-
gle treatments. However, combination of ATO/Indo induced
phosphorylation of p38 at 4 hrs and increased phospho-p38
to a remarkable level at 24 hr, suggesting a synergistic effect
of combination treatment on p38 pathway activation.
3.6. Both ATO and Indo Activate Caspase-3. To address the
role of caspase-3 in the cytotoxicity of ATO, Indo, and
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Indo, and ATO/Indo combination.
ATO/Indo combination, the caspase-3 activity wasmeasured.
As shown in Figure 7, caspase-3 activity increased 1.2 and 1.6
fold with ATO 2 𝜇M and Indo 10 𝜇M, respectively. Increase
in the caspase-3 activity in the cells treated with combination
of ATO 2𝜇M and Indo 10 𝜇M was similar to that of Indo
10 𝜇M. Caspase-3 inhibitor-treated cell lysate control showed
that perhaps some other caspases are being activated in the
treated cells.
4. Discussion
Combination therapy with agents that hire different signal-
ing pathways is a promising strategy for overcoming drug
resistance in cancerous cells and for increasing treatment
efficacy and/or decreasing drug toxicity [27]. The present
findings indicate that Indo increases the cytotoxicity of ATO
in human lung cancer cell line A549. This event is associated
with activation of ERK and p38 MAPK signaling pathways.
Our study showed that ATO, Cel, and Indo dose-
dependently decreased cell viability (IC
50
s are 68.7, 98.2, and
396.5 𝜇M, resp.). Considering this effect, Indo produces very
weak effect (IC
50
= 396.5 𝜇M) compared to two other drugs.
It has been shown that ATO mediates its cytotoxic effect
by induction of apoptosis via disruption of mitochondrial
transmembrane potentials and caspase-3 activation in var-
ious cell lines and human lymphocytes [18, 28]. Therefore,
the cytotoxic effect of arsenic is related to apoptotic pathways
since caspase-3 has been activated (Figure 7). On the other
hand, accumulating body of evidence suggests that COX
enzymes, especially COX-2, have been increased in many
cancers including lung cancers [4, 6]. Thus, the inhibition of
COX enzymes and in particular COX-2 can be accounted for
the cytotoxic effect of Cel and Indo treatments. However, our
results indicate a dramatic cytotoxicity with combinations
of nontoxic doses of Cel or Indo with ATO in A549 cells
(Figure 3). These results are of importance since very low
doses of ATO and Indo (or Cel) have exerted significant
cytotoxicity.TheATO/Indo combination treatment produced
synergistic effect in all doses of ATO/Indo. Several combi-
nations of NSAIDs with other chemopreventive drugs have
previously been investigated in the lung cancers [22–24, 29,
30]. Lines of evidence show that anticancer effects of NSAIDs
are not totally dependent on selectivity of COX-2 inhibition
[9, 10, 31].This perhaps justifies the difference in the observed
effects of Indo/ATO and Cel/ATO combinations. In this
regard, we have tested change in COX-2 expression (at
mRNA and protein level) as well as several apoptosis-related
proteins fromMAPKs pathways as potential mechanisms for
the observed enhanced cytotoxicity of indo/ATO combina-
tion. ATO dose-dependently has decreased COX-2 mRNA
expression (Figure 4(a)); however at low dose (2 𝜇M), ATO
has opposed the increase in COX-2 expression induced
by Indo (Figure 4(c)). This is in consistent with the Han
et al. [32] report that shows ATO decrease expression of
COX-2. Besides, Dex has strong inhibitory effect on COX-2
expression (Figure 5) and little cytotoxic effect in these cells.
When we evaluated the caspase-3 activation, ATO (2𝜇M)
and Indo (10 𝜇M) (as single or combination) have increased
caspase-3 activation and therefore induced apoptosis.
Changes in expression of the proteins ofMAPK pathways
have not been prominent except decreasing in p38, ERK1/2,
and Akt proteins with ATO 50𝜇M. However, activation of
phospho-ERK and phospho-p38 is noticeable when com-
bination of ATO 2 𝜇M and Indo 10 𝜇M has been used.
These findings are in agreement with other studies that have
reported activation of MAPK pathways with ATO and Indo
alone [19, 21, 33]. MAPKs including ERK1/2, p38, and JNK
havemany important regulatory roles in the proliferation and
apoptosis of the cells [34]. In general, JNK and p38 pathways
are activated by stress stimuli and are involved in apoptosis,
while ERK1/2 pathway is preferentially activated in response
to growth factors [35]. Whereas ERK activation has generally
been associated with antiapoptotic effects, activation of ERK
has also been shown to be necessary for the cytotoxic-
induced apoptosis [36]. We have previously shown that ATO
treatment increases p38 and ERK expression in promyelocyte
of APL patients [21]. Thus changes in MAPK pathways could
be accounted for the ATO effect.
To our knowledge based on a search of literature no study
has been conducted to assess the combination of Indo and
ATO on the cancerous cells. Instead, in several studies the
antiproliferative and apoptotic effects of sulindac, a structural
isoform of indomethacin, have been studied. In a study on
the NCI-H157 human lung cancer cells, Park et al. [37]
showed that combination of ATO (2.5 𝜇M) and sulindac
(5 𝜇M) increased apoptosis, reactive oxygen species (ROS),
and oxidative stress, as evidenced by the heme oxygenase-
1 (HO-1) expression and phosphorylation of ERK. Jin et al.
[22] studied combination effect of ATO (1𝜇M) and sulindac
(200𝜇M) on the H1299 human nonsmall cell lung carcinoma
cells.They noted collapse ofmitochondrialmembrane poten-
tial and activation of caspase-3 in the cells cotreated with
sulindac/ATO. Furthermore, the authors reported activation
of JNK downstream of ROS generation. We here report
phosphorylation of ERK in ATO/Indo treated cells and a
strong activation of p38 kinase which can be involved in
mediated stress induced cell death. However, ATO/Indo
activated phosphorylation of p38 is in contrast with Jin et al.
findings [22].Thismay be due to cell type and/or involvement
of this pathway in cytotoxicity.
The effect of low doseATO/indo combination on cytotox-
icity of A549 can be a multiple pathway function. It has been
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shown that indomethacin induces apoptosis in vivo [38] and
in vitro in some cancerous cells including lung [7, 8], colon
[39, 40], and leukemia [41]. In this report, production of ROS
has been mentioned as the main mechanism of apoptotic
effect [42, 43]. Besides, ROS also plays an important role in
the ATO-induced apoptosis and cell death [28]. Consistent
with this hypothesis, accumulating evidence indicates that L-
buthionine-sulfoximine (BSO), a drug that depletes intracel-
lular glutathione (GSH) and generates ROS, can sensitize the
lung cancerous cells to ATO-induced cell death [24, 42, 44–
46]. Moreover, ROS can activate ERK1/2 pathway [47] as
well as p38 kinase [47, 48]. Thus, increase in p38 kinase and
ERK activation besides change in COX-2 expression can be
accounted for the ATO/indo induction of apoptosis in low
doses.
5. Conclusion
In conclusion we here report a combination of low doses
of ATO and indomethacin as strong inducer of apoptosis in
A549. This finding is important since the doses of ATO and
indomethacin are practically noneffectivewhenused as single
treatment. Thus, low dose combination may provide better
treatment with less adverse effect in patient which needs to
be studied in future.
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